Baseline Characteristics of Participants in ARCHER II: A Phase 3 Study of Vision Protection of Vonaprument, a C1q Inhibitor, in Dry AMD with GA

Roberto Gallego-Pinazo, MD PhD[1] on behalf of the ARCHER and ARCHER II Investigators

[1] Unit of Macula and Clinical Trials, Oftalvist Clinic, Valencia, Spain

Disclosures

Advisory Board

- ADARx Pharmaceuticals
- Alfasigma
- Apellis
- Annexon
- EyeBio (MSD)
- Heidelberg Engineering
- Johnson & Johnson
- ORA Clinical
- Regeneron
- Roche
- Samsung Bioeps

Research Support

- ADARx Pharmaceuticals
- Annexon
- Astellas
- Celltrion
- EyeBiotech
- Gyroscope
- Heidelberg Engineering
- Ionis
- Iveric Bio
- Johnson & Johnson
- MSD
- Novartis
- Regeneron
- Roche
- Shanghai Henlius Biotech
- Stealth Therapeutics

ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Patients with Dry AMD and GA

Randomized, double-masked
Included **foveal and non-foveal** lesions
Stratified for lesion location and lesion size
12 months (n=270)

- **Sham**
  monthly or every other month
  (n=89)
- **Vonaprument 5mg**
  every other month (EOM)
  (n=92)
- **Vonaprument 5mg**
  monthly (EM)
  (n=89)

PRIMARY ENDPOINT

Rate of Change in GA lesion area as assessed by fundus autofluorescence at Month 12

PRESPECIFIED FUNCTIONAL ANALYSES

Best Corrected Visual Acuity (BCVA)
Low Luminance Visual Acuity (LLVA) & Deficit (LLVD)

Off-treatment
(6 months)

END OF STUDY
Month 18

ARCHER Phase 2: Dose-Dependent Vision Protection at Month 12 and Over Time

PARTICIPANTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12#

Month 12 event confirmed at month 15



	Sham	Vonaprument EOM	Vonaprument EM
Nominal p-value vs sham^	---	.0994	.0076

#Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit; visits were monthly through Month 12 and then at Months 15 and 18
^Nominal p-value from a Chi-square test in ITT population: *Nominal p < .05

PROBABILITY OF CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12#



#Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit
HR, hazard ratio; Nominal log-rank test (versus sham) p-values are presented; *Nominal p < 0.05\

ARCHER Phase 2: Dose-Dependent Vision Protection in Both Healthier and Less Healthy Eyes

Profound effect seen in treating healthier eyes

PARTICIPANTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12[#]



[#]15-LL Event Definition – confirmed loss of 15 or more letters by BCVA at two consecutive visits including month 12 supported month 15; Events: n = 27

ARCHER Phase 2: Dose–Dependent Vision Protection in Participants with Foveal and Non-Foveal Lesions

PARTICIPANTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12[#]



[#]15-LL Event Definition – confirmed loss of 15 or more letters by BCVA at two consecutive visits including month 12 supported month 15; Events: n = 27

Key ARCHER Attributes Replicated in Larger, Longer ARCHER II Design

ARCHER
Phase 2



PRIMARY ENDPOINT

Rate of change in GA lesion area as assessed by fundus autofluorescence at Month 12

ARCHER II
Phase 3



PRIMARY ENDPOINT

Proportion of patients who experience a BCVA ≥15-Letter Loss confirmed at two consecutive visits

ARCHER II Participant Demographics and Structural Characteristics Consistent with ARCHER Population

BASELINE DEMOGRAPHICS AND STRUCTURAL CHARACTERISTICS	ARCHER (N = 270)	ARCHER II (N = 659)
Age, mean (SD)	80.0 (8.2)	78.4 (8.0)
Gender (% Female)	61.5%	63.0%
GA Lesion Size (mm^2), mean (SD)	7.36 (4.01)	7.23 (3.49)
GA Lesion Location (% Subfoveal)	51.9%	54.8%
Total EZ Loss, mm^2 (% of Total Area Lost)	12.7 (35.3%)	12.3 (34.3%)

BASELINE VISUAL ACUITY MEASURES	ARCHER (N = 270)	ARCHER II (N = 659)
Mean BCVA (SD)	58.4 (16.2)	65.8 (10.5)
Baseline BCVA <45 Letters	23.3%	0.0%*
15-LL Events w Baseline BCVA <45 Letters	1	--
15-LL Events w Baseline BCVA ≥45 Letters	26	--
Mean LLVA (SD)	33.0 (16.9)	38.3 (17.2)
Mean LLVD (SD)	25.7 (16.9)	27.6 (15.6)
LLVD < 30 Letters	62.4%	60.7%

*Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER

ARCHER II Study Design Optimized to Assess Vision Protection

- ARCHER demonstrated dose dependent vision protection with vonaprument treatment across key measures of visual acuity and across patient populations

- ARCHER II design consistent with ARCHER study demographics and baseline characteristics

- ARCHER II population replicates those with large treatment effects seen in ARCHER
  - Foveal lesions at baseline: more than 50% of the study population
  - Baseline LLVD < 30: more than 60% of the study population

- Anticipated communications on track for Month 15 primary endpoint in Q4 2026 and Month 24 primary endpoint in Q3 2027